S
Sarah S. Bernards
Researcher at University of Washington
Publications - 11
Citations - 887
Sarah S. Bernards is an academic researcher from University of Washington. The author has contributed to research in topics: Ovarian carcinoma & Cancer. The author has an hindex of 7, co-authored 9 publications receiving 614 citations.
Papers
More filters
Journal ArticleDOI
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist,Maria I. Harrell,Mark F. Brady,Tom Walsh,Ming K. Lee,Suleyman Gulsuner,Sarah S. Bernards,Silvia Casadei,Qian Yi,Robert A. Burger,John K. Chan,Susan A. Davidson,Robert S. Mannel,Paul DiSilvestro,Heather A. Lankes,Nilsa C. Ramirez,Mary Claire King,Elizabeth M. Swisher,Michael J. Birrer +18 more
TL;DR: To determine the frequency and importance of germline mutations in cancer-associated genes in OC, a study population of 1915 women with OC and available germline DNA was identified and mutations were compared with the National Heart, Lung, and Blood Institute GO Exome Sequencing Project (ESP) and the Exome Aggregation Consortium (ExAC).
Journal ArticleDOI
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.
Barbara M. Norquist,Mark F. Brady,Maria I. Harrell,Tom Walsh,Ming K. Lee,Suleyman Gulsuner,Sarah S. Bernards,Silvia Casadei,Robert A. Burger,Krishnansu S. Tewari,Floor J. Backes,Robert S. Mannel,Gretchen E. Glaser,Cheryl Bailey,Stephen C. Rubin,John T. Soper,Heather A. Lankes,Nilsa C. Ramirez,Mary Claire King,Michael J. Birrer,Elizabeth M. Swisher +20 more
TL;DR: HRR mutations, including non-BRCA genes, significantly prolong PFS and OS in ovarian carcinoma and should be stratified for in clinical trials.
Journal ArticleDOI
Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Sarah S. Bernards,Kathryn P. Pennington,Maria I. Harrell,Kathy Agnew,Rochelle L. Garcia,Barbara M. Norquist,Elizabeth M. Swisher +6 more
TL;DR: Patients with BRCA1-methylated carcinomas share clinical characteristics with patients with BEC1-mutated carcinoma including younger age and predominantly HGS histology, however, unlike mutation, RAD51C and BRCa1 methylation were not associated with improved survival or greater sensitivity to platinum chemotherapy.
Journal ArticleDOI
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
Christopher B. Morse,Mirna N. Toukatly,Mark R. Kilgore,Kathy Agnew,Sarah S. Bernards,Barbara M. Norquist,Kathryn P. Pennington,Rochelle L. Garcia,John B. Liao,Elizabeth M. Swisher +9 more
TL;DR: Patients that have both CD3+ TILs and HRD OC are afforded the greatest improvement in overall survival, and this finding may have therapeutic implications for OC patients treated with emerging immunotherapies.
Journal ArticleDOI
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
Roshni Kalachand,Britta K. Stordal,Stephen F. Madden,Benjamin C. Chandler,Julie M. Cunningham,Ellen L. Goode,Ilary Ruscito,Ilary Ruscito,Elena Ioana Braicu,Jalid Sehouli,Atanas Ignatov,Herbert Yu,Dionyssios Katsaros,Gordon B. Mills,Karen H. Lu,Mark S. Carey,Kirsten Timms,Jolanta Kupryjanczyk,Iwona K. Rzepecka,Agnieszka Podgorska,Jessica N. McAlpine,Elizabeth M. Swisher,Sarah S. Bernards,Ciaran O'Riain,Sharon O'Toole,John J. O'Leary,David D.L. Bowtell,David Thomas,Katharina Prieske,Simon A. Joosse,Linn Woelber,Parvesh Chaudhry,Norman Häfner,Ingo B. Runnebaum,Bryan T. Hennessy,Bryan T. Hennessy,Bryan T. Hennessy +36 more
TL;DR: BRCA 1-methylated OC displays similar clinico-pathological features to BRCA1-mutated OC, but is not associated with survival.